Rekombinanter CD22 (Epratuzumab Biosimilar) Antikörper

Produktnummer ABIN7795108

Der Humanized Monoklonal anti-CD22 (Epratuzumab Biosimilar) Antikörper (ABIN7795108) detektiert spezifisch CD22 (Epratuzumab Biosimilar) in FACS und in vivo. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Rekombinanter CD22 (Epratuzumab Biosimilar) Antikörper (ABIN7795108)

Target: CD22 (Epratuzumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Humanized

Klonalität: Monoklonal

Konjugat: Dieser CD22 (Epratuzumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-CD22 (Epratuzumab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Epratuzumab Biosimilar, Endotoxin 0.05 EU/mg

Produktmerkmale: Epratuzumab Biosimilar uses the same protein sequences as the therapeutic antibody epratuzumab. Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus. Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: Less than 0.5 EU/mg of protein as determined by LAL method

Immunogen: Human CD22

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu CD22 (Epratuzumab Biosimilar)

Target: CD22 (Epratuzumab Biosimilar)

Andere Bezeichnung: Epratuzumab Biosimilar

Substanzklasse: Biosimilar